Abstract
PURPOSE
The treatment of childhood nasopharyngeal carcinoma has been adapted from adult regimens; pediatric-specific studies are limited. The ARAR0331 study sought to evaluate the impact of induction chemotherapy (IC) and concurrent chemoradiotherapy (CCR).
PATIENTS AND METHODS
Patients with American Joint Committee on Cancer stages IIb to IV were scheduled to receive three cycles of IC with cisplatin and fluorouracil, followed by CCR with three cycles of cisplatin. Patients with complete or partial response to IC received 61.2 Gy to the nasopharynx and neck, and patients with stable disease received 71.2 Gy.
RESULTS
Between February 2006 and January 2012, 111 patients (75 male) were enrolled. Median age was 15 years, and 46.8% of the patients were African American. After a feasibility analysis, the study was amended to reduce cisplatin to two cycles during CCR. The 5-year event-free survival (EFS) and overall survival estimates were 84.3% and 89.2%, respectively. The 5-year EFS for stages IIb, III, and IV were 100%, 82.8%, and 82.7%, respectively. The 5-year cumulative incidence estimates of local, distant, and combined relapse were 3.7%, 8.7%, and 1.8%, respectively. Patients treated with three versus two CCR cycles of cisplatin had improved 5-year postinduction EFS (90.7% v 81.2%, P = .14).
CONCLUSION
Patients in ARAR0331 were characterized by advanced disease and by a high proportion of black children and adolescents. Treatment with IC and CRT resulted in excellent outcomes. A radiation dose reduction is possible for patients responding to IC. Although the outcomes are comparable, we observed a trend toward decreased EFS for patients assigned to receive fewer doses of cisplatin during CCR.
INTRODUCTION
Nasopharyngeal carcinoma (NPC) is rare in children,1,2 accounting for only 2% of cases.3 Most cases occur in adolescent male children; virtually all are of WHO type II or III histology and are associated with Epstein-Barr virus; and cases present at more advanced stages than in adults.3 In the United States, NPC is more prevalent among black children.3,4
Treatment of childhood NPC has traditionally used induction chemotherapy (IC) to reduce radiation, and long-term survival has been achieved for 60% to 80% of patients.2,5-9 In recent years, on the basis of evidence of the superiority of concurrent chemoradiotherapy (CCR) regimens,10,11 the treatment of childhood NPC has evolved to incorporate this approach.12-16
The impact of combining IC and CCR has been investigated in several randomized clinical trials in adults.17-22 A recent update of the Meta-Analysis of Chemotherapy in Nasopharyngeal Collaborative Group (MAC-NPC) showed the superiority of IC and CCR over CCR alone for progression-free survival, locoregional control, and distant control.11
Children and adolescents with NPC have been excluded from those randomized clinical trials, and the potential differences in pathogenesis limit the extrapolation of the adult data to inform the development of standard-of-care guidelines. In the absence of the numbers required to conduct randomized clinical trials, single-arm studies can provide validation while offering the opportunity to further characterize the disease in this young population.
Building on past cooperative group experience piloting the use of IC and radiation therapy,6 the Children’s Oncology Group developed the ARAR0331 protocol to assess the feasibility and efficacy of IC followed by response-adapted CCR in children and adolescents with NPC.
PATIENTS AND METHODS
Eligibility
Patients younger than 19 years of age with NPC WHO type II or III and adequate performance were eligible for enrollment. Patients with uncontrolled infections and women who were pregnant or breastfeeding were ineligible. The trial was approved by the Pediatric Central Institutional Review Board of the National Cancer Institute and by the institutional review boards of participating institutions, as required. Informed consent from the patient, or parent or guardian as appropriate, was obtained before enrollment.
Treatment
Patients were staged using the American Joint Committee on Cancer (AJCC) staging system for NPC 5th edition.23 Patients with AJCC stages I and IIa (stratum A) were to be treated with radiation therapy only (stage I, 61.2 Gy; stage IIa, 66.6 Gy). Patients with AJCC stages IIb to IV (stratum B) were to receive three cycles of IC with cisplatin (80 mg/m2 day 1) and fluorouracil (1,000 mg/m2/d continuous infusion days 1 to 4), administered every 21 days, followed by consolidation consisting of radiation therapy and three cycles of cisplatin (100 mg/m2), administered every 21 days. Radiation therapy was planned to target the cervical lymph node regions I to V and the primary tumor and nasopharynx to a dose of 45 Gy followed by response-based radiation to the nasopharynx and gross nodal disease. For patients with complete or partial response after induction chemotherapy, a dose of 61.2 Gy was administered to the entire nasopharynx and any residual enhancing mass with a 1 cm margin at the time of planning. Residual lymph node disease was targeted to include the entire lymph node level with a 1 cm margin to a dose of 61.2 Gy. Patients with stable disease received 70.2 Gy using an identical targeting approach. Either intensity-modulated radiation therapy or three-dimensional conformal radiation therapy was required for this trial. Given the evidence demonstrating the efficacy of amifostine for the prevention of xerostomia in adults with head and neck cancer at the time of the trial design,24 amifostine per day was prescribed before radiation therapy (200 mg/m2 subcutaneously).
Statistical Methods
Primary study analysis.
The primary study analysis for AJCC stage IIb to IV (stratum B) patients was a comparison of the observed 2-year event-free survival (EFS), with the target value of 70% as taken from POG-9486, the previous COG study.6 EFS was defined as the time from study enrollment to disease progression, diagnosis of a second malignancy, death, or last follow-up. EFS as a function of time since enrollment was estimated using the method of Kaplan and Meier.25 Median follow-up for EFS analysis was calculated by the reverse–Kaplan-Meier methods as suggested by Schemper and Smith.26 The test statistic for the primary analysis was the complementary log-log estimate of 2-year EFS minus log(-log(0.7)) divided by its SD.27 If the one-sided P value associated with the alternative hypothesis that the true 2-year EFS was greater than 0.70 was .05 or less, the treatment was to be considered significantly superior to the historical result.
The initial version of the protocol was designed to accrue 144 patients to stratum B. This provided 90% power to identify 2-year EFS as superior to the target value when the true 2-year EFS was 80%. Because of slower than expected enrollment at 26 months of trial initiation, the required number of stratum B patients to be accrued was reduced to 111. This provided 79% power to identify 2-year EFS as superior to the target value when the true 2-year EFS was 80%.
Tolerability of delivering three cisplatin cycles during CCR was to be assessed in all eligible stratum B patients who started consolidation and did not have the dose of cisplatin reduced or eliminated during induction. Patients who had cisplatin reduced at least once during radiation or who electively terminated CCR or who died because of complications were considered to have experienced an intolerability event. Patients who completed CCR or who were removed from protocol therapy for disease progression, second malignancy, or death unrelated to protocol were considered not to have experienced an intolerability event.
The protocol was designed to consider an expected 130 intolerability-evaluable patients; if 32 or more experienced an intolerability event, the therapy was to be considered for modification. If the true intolerability event rate was 30%, the therapy would be identified for modification with probability 0.93. If the true intolerability event rate was 20%, therapy would be identified for modification with probability 0.12. The COG Data Safety and Monitoring Committee requested an analysis of intolerability 26 months after the start of enrollment. At that time, nine of 21 intolerability-evaluable patients had experienced an intolerability event (decreased renal function in one patient and multiple toxicities in eight patients, including GI toxicity in five and renal dysfunction in two). As a result, the study committee recommended modification of CCR by omitting the last of the three postinduction cycles of cisplatin.
Exploratory analyses.
Overall survival (OS) was defined as the time from study enrollment until death regardless of cause or last patient follow-up. OS as function of time since enrollment was estimated using the method of Kaplan and Meier.25 The cumulative incidence of each type of EFS event as a function of time since enrollment was estimated by the method of Gray.28
To assess the effect of the reduction of intensity of CCR from three to two cycles of cisplatin, all eligible patients who started consolidation were classified into two groups according to treatment (three v two cycles). Two outcome measures, EFS after induction (EFS-PI) and OS after induction, were defined, with the time from enrollment to the start of consolidation subtracted from the particular measure. EFS-PI and OS after induction as a function from time since the start of consolidation were calculated using the method of Kaplan and Meier.25 The cumulative incidence of each type of EFS-PI event as a function of time since the completion of induction was estimated by the method of Gray.28 Statistical testing for differences in risks for EFS-PI event and death after induction according to patient characteristics and consolidation plan was conducted using the log-rank test.27 The trend test27 was used for comparisons of stage. Statistical testing for differences in risk for the various event types identified in the cumulative incidence analyses were conducted using Gray’s test.28 Two-sided testing was used. A P value of ≤ .05 was considered significant. No adjustment was made for multiplicity of testing for these exploratory analyses.
Toxicity analysis.
The probability of grade 3 or higher toxicity was estimated for three treatment blocks: induction, three-cycle consolidation, and two-cycle consolidation. For each eligible patient who started a treatment block, the maximum grade of every Common Terminology Criteria for Adverse Events version 4 adverse event was determined. The number of patients who experienced grade 3 or higher toxicity was divided by the number of patients evaluated for toxicity in that block to provide an estimate of the probability of the particular toxicity.
RESULTS
The trial opened in February 2006 and closed in January 2012; 111 patients were accrued and included in the outcome analyses, using data current to December 2018 (Fig 1). All patients had AJCC stage IIb to IV and received stratum B treatment. Patient characteristics are listed in Table 1, and grade 3 or higher adverse events are included in Appendix Table A1 (online only). Median age at the time of enrollment was 15 years, and two thirds of the patients were male. The majority of patients (46.8%) were African American, and 59 (53%) had stage IV disease.
FIG 1.
CONSORT diagram of ARAR0331. XRT, radiation therapy.
TABLE 1.
Patient Characteristics

Primary Analysis
Twenty-three events were observed: 10 patients with local-only relapse, nine with distant-only relapse, two with local plus distant relapse, one second malignant neoplasm (epithelioid sarcoma of the floor of the mouth), and one accidental death. The point estimate of the 2-year EFS was 86.9%. The value of the test statistic described previously was −3.47, which corresponds to a P value of .00026. Thus, ARAR0331 therapy was considered to significantly increase the 2-year EFS when compared with the design target for the trial.
With a median follow-up of 63 months, the 5-year EFS and OS estimates were 84.3% (95% CI, 75.6% to 90.2%) and 89.2% (95% CI, 80.7% to 94.1%), respectively (Fig 2). The 5-year EFS estimates for stages IIb, III, and IV were 100%, 82.8% (95% CI, 65.1% to 92%), and 82.7% (95% CI, 70.2% to 90.3%), respectively (P = .18; Fig 3). The 5-year EFS estimates for patients with stage IV disease were 85.1% (95% CI, 67.8% to 93.5%), 88.5% (95% CI, 61.4% to 97%), and 57.1% (95% CI, 17.2% to 83.7%), for stages IVA, IVB, and IVC, respectively. The presence of metastases at diagnosis was significantly associated with a worse outcome; the 5-year EFS estimates were 86.3% (95% CI, 77.3% to 91.8%) versus 57.1% (95% CI, 17.2% to 83.7%) for patients without and with metastases, respectively (P = .006). There were no differences in outcome by age (younger than 14 years of age and 14 years of age and older), sex, race (white v black v other) or ethnicity (Hispanic v non-Hispanic).
FIG 2.
Event-free survival and overall survival probabilities for 111 patients enrolled in ARAR0331.
FIG 3.
Event-free survival probabilities by stage.
The study did not include central response review, and radiation dose was administered at the institution’s discretion on the basis of the protocol recommendations. Three patients had progressive disease during IC, eight patients were removed from protocol at the decision of the treating physicians or at the request of the patient or family, and three patients were not considered evaluable for radiation dose evaluation. Of the remaining 97 patients who completed CCR, 18 patients (18.6%) received 70.2 Gy, four patients (4.1%) received doses between 63.9 Gy and 66.6 Gy, and 75 patients (77.3%) received a dose of 61.2 Gy or lower (range, 57.6 to 61.2 Gy; median, 61.2 Gy).
The 5-year cumulative incidence estimates of local, distant, and local plus distant relapse were 3.7% (95% CI, 1.4% to 9.5%), 8.7% (95% CI, 4.6% to 16.2%), and 1.8% (95% CI, 0.5% to 7.1%), respectively (Fig 4).
FIG 4.
Cumulative incidence of relapse by type.
Exploratory Analyses
To investigate the effect of cisplatin reduction during consolidation as a result of the feasibility amendment, we compared outcomes for patients who started consolidation when three (44 patients) versus two (61 patients) cycles of cisplatin were planned. There was a trend toward a better outcome for patients who were treated with three cycles, with a 5-year EFS-PI estimate of 90.8% (95% CI, 77.3% to 96.4%), versus 81.1% (95% CI, 67.1% to 89.6%) for patients who received two cycles (P = .14). The 5-year cumulative incidence of relapse was 8.4% (95% CI, 3.3% to 20.9%) for patients treated before the amendment, versus 17.1% (95% CI, 9.2% to 30.5%) for patients treated after the amendment (P = .11). There were no differences in the 5-year postinduction cumulative incidence of local (2.3% [95% CI, 0.2% to 10.7%] v 3.3% [95% CI, 0.8% to 10.2%] for three v two cycles, P = .75) or combined local and distant relapse (2% [95% CI, 0.2% to 10%] v 1.7% [95% CI, 0.14% to 7.9%] for three v two cycles, P = .82). However, there was a trend toward an increased cumulative incidence of distant relapse for patients receiving lower cumulative doses of cisplatin; the 5-year cumulative incidence of distant relapse was 4.6% (95% CI, 0.8% to 13.9%) for patients receiving three cycles and 11% (95% CI, 4.3% to 21%) for patients receiving two cycles (P = .13; Fig 5). Finally, we compared tolerability between patients treated with three versus two cycles of cisplatin during CRT. Among the 104 tolerability-evaluable patients who started consolidation, an intolerability event occurred in 43.2%, versus 18.3% in patients receiving three versus two cycles of cisplatin, respectively.
FIG 5.
Cumulative incidence of types of relapse after induction according to planned consolidation therapy. The red dashed line represents assignment to two cycles of cisplatin; the blue solid line represents three cycles of cisplatin.
DISCUSSION
To our knowledge, we report the largest prospective trial in childhood NPC exploring the use of IC and CCR. In the absence of a control group, it is not possible to assess the full impact of the intervention, but all outcome end points, including progression-free survival, OS, and locoregional and distant control, seem to be superior to most reported adult clinical trials.
Several meta-analyses of randomized clinical trials data have documented the advantage of CCR over radiation therapy for progression-free survival, local and distant control, and cancer mortality.10,11,17,18,29-32 Although the role of induction and adjuvant chemotherapy is more controversial, analyses performed by the MAC-NPC group including data from 20 trials and 5,144 patients have shown an advantage to the addition of induction or adjuvant chemotherapy to CCR.11 Two other meta-analyses limited to randomized trial data evaluating the addition of IC to CCR and three recently reported randomized clinical trials have confirmed the favorable impact of IC.17,18,20-22
Children and adolescents are excluded from adult trials; thus, the importance of conducting pediatric-specific validation studies before evidence is generalized. This is particularly relevant considering the unique epidemiologic features of NPC.33,34 First, the incidence of NPC is higher among black children and adolescents3,5; this race group represented more than 40% of our study population, compared with less than 10% among adults.3 Likewise, in the United States, 43.2% of adults with NPC are Asian or Pacific Islanders, compared with only 15.5% of children and adolescents.3 Second, NPC presents more aggressively in young patients; in a population-based study, 46% of patients younger than 19 years of age had stage IV, compared with 36% in adults.3 These differences must be considered when analyzing clinical trial data. For example, 53% of patients in ARAR0331 had stage IV, compared with 41% of adults enrolled in the randomized clinical trials from which evidence has been generated.10 Despite the more advanced presentation in children and adolescents, their outcomes seem to be superior to adults, as shown by population-based analyses and confirmed by our data.3
Thus, a better characterization of the disease and its response to treatment as it relates to the different racial and age groups is required to generate recommendations. Over the past decade, a series of small cohort studies have reported outcomes for children and adolescents using IC and CCR. Five-year EFS and OS ranged from 55.8% to 79.3% and from 78% to 85.7%, respectively.8,12-16 The best results have been produced by the German NPC-2003-GPOH/DCOG protocol, with an EFS of 92.4% and an OS of 97.1% at a median of 30 months.14 A differing feature of this trial was the addition of interferon beta as maintenance therapy for its antiviral and antitumoral properties.35 However, these results must be interpreted with caution; first, the study’s short follow-up of 30 months limits proper comparison with ARAR0331, and second, the patient cohort was characterized by significantly lower stages (2% stage IVB-IVC v 22.5% in ARAR0331).
Treatment of NPC is associated with significant acute and late effects, a significant proportion of which are related to the high radiation doses used.11,36-38 For this reason, ARAR0331 used a response-based approach and explored decreasing radiation to 61.2 Gy for patients with a response to IC. Seventy-seven percent of the patients received the planned reduced radiation doses; the low cumulative incidence of local (3.7%) and combined local and distant (1.8%) recurrence confirms the feasibility of this approach and suggests that additional dose reductions to decrease the severity of long-term effects, such as neck fibrosis, may be possible, as noted by others.7,8,14,15 The assessment of metabolic response with positron emission tomography may help further refine response-based radiation.39,40
The benefit of CCR may be diluted when toxicity limits treatment delivery; the dose of cisplatin received during radiation has been shown to influence locoregional control and OS.10,41 This is particularly relevant in regimens that include IC, because the cumulative toxicity as patients enter the local control phase may limit compliance; randomized trials have reported a lower dose intensity of cisplatin during radiation compared with patients receiving CCR only,19,21 and delayed initiation of radiation therapy in patients receiving IC has been associated with worse outcomes.42 A similar phenomenon occurred in our trial, in which the cumulative dose of cisplatin during radiation therapy was decreased because of poor tolerance. The trend toward improved outcomes for patients treated in the higher-dose cohort highlights the need to develop feasible regimens that maximize cisplatin exposure and its synergism with radiation.
Our trial was not designed to assess long-term toxicities; however, our long follow-up allowed us to assess the risk of second cancers. Late-effect studies of adults treated with modern therapies have not reported an incidence of second malignant neoplasms,36,37,43 and thus, proper comparisons are not possible. One patient developed a head and neck sarcoma, for a 5-year cumulative incidence of a second cancer of 1.8%; this risk is lower than that reported previously in historical cohort studies.5 Although a longer follow-up is required, modern radiation techniques are likely to lower this risk. The recent development of cell and immune therapies for NPC, such as Epstein-Barr virus cytotoxic lymphocytes44-46 and checkpoint inhibitors,47,48 holds the promise of further advancing care with less toxic treatments. This is particularly relevant in children and adolescents, where long-term effects of therapy may severely influence quality of life.
In summary, we have reported the largest prospective trial for childhood NPC, to our knowledge, and we have further defined the differences between this unique age group and adults, and we have shown among the highest survival estimates, close to 90% at 5 years, using a combination of IC and CCR. Additional advances in the treatment of NPC will require the development of clinical trials that encompass a broader age spectrum but consider the unique features of this young population.
APPENDIX
TABLE A1.
Grade 3 or 4 Adverse Events as Coded With CTCAE Version 4
Footnotes
Supported by Chair’s Grant U10 CA98543, National Clinical Trials Network Operations Center Grant U10CA180886, Statistics and Data Center Grant U10 CA98413, and National Clinical Trials Network Statistics and Data Center Grant U10CA180899 of the Children’s Oncology Group; by Imaging and Radiation Oncology Core Grant U10 CA29511 from the National Cancer Institute, National Institutes of Health; and by the St Baldrick’s Foundation.
Clinical trial information: NCT00274937.
Listen to the podcast by Dr Wolden at http://ascopubs.org/jco/podcasts
AUTHOR CONTRIBUTIONS
Conception and design: Carlos Rodriguez-Galindo, Mark D. Krailo, John Hicks, Alberto S. Pappo
Provision of study material or patients: Matthew J. Krasin, Li Huang
Collection and assembly of data: Carlos Rodriguez-Galindo, Mark D. Krailo, Matthew J. Krasin, M. Beth McCarville, John Hicks
Data analysis and interpretation: All authors
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children’s Oncology Group ARAR0331 Study
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.
Mark D. Krailo
Consulting or Advisory Role: Merck Sharp & Dohme
Travel, Accommodations, Expenses: Merck Sharp & Dohme
M. Beth McCarville
Consulting or Advisory Role: GE Healthcare
Alberto S. Pappo
Honoraria: Bayer AG, Roche
Consulting or Advisory Role: Merck, Loxo/Bayer AG
No other potential conflicts of interest were reported.
REFERENCES
- 1.Ayan I, Kaytan E, Ayan N. Childhood nasopharyngeal carcinoma: From biology to treatment. Lancet Oncol. 2003;4:13–21. doi: 10.1016/s1470-2045(03)00956-2. [DOI] [PubMed] [Google Scholar]
- 2.Dourthe ME, Bolle S, Temam S, et al. Childhood nasopharyngeal carcinoma: State-of-the-art, and questions for the future. J Pediatr Hematol Oncol. 2018;40:85–92. doi: 10.1097/MPH.0000000000001054. [DOI] [PubMed] [Google Scholar]
- 3.Sultan I, Casanova M, Ferrari A, et al. Differential features of nasopharyngeal carcinoma in children and adults: A SEER study. Pediatr Blood Cancer. 2010;55:279–284. doi: 10.1002/pbc.22521. [DOI] [PubMed] [Google Scholar]
- 4.Greene MH, Fraumeni JF, Hoover R. Nasopharyngeal cancer among young people in the United States: Racial variations by cell type. J Natl Cancer Inst. 1977;58:1267–1270. doi: 10.1093/jnci/58.5.1267. [DOI] [PubMed] [Google Scholar]
- 5.Cheuk DKL, Billups CA, Martin MG, et al. Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma. Cancer. 2011;117:197–206. doi: 10.1002/cncr.25376. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Rodriguez-Galindo C, Wofford M, Castleberry RP, et al. Preradiation chemotherapy with methotrexate, cisplatin, 5-fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma. Cancer. 2005;103:850–857. doi: 10.1002/cncr.20823. [DOI] [PubMed] [Google Scholar]
- 7.Al Mousa A, Abu-Hijlih R, Salem A, et al. Induction methotrexate, cisplatin, and 5-fluorouracil versus cisplatin and 5-fluorouracil followed by radiotherapy in pediatric nasopharyngeal carcinoma: A retrospective analysis in a tertiary cancer center. J Pediatr Hematol Oncol. 2017;39:e437–e442. doi: 10.1097/MPH.0000000000000933. [DOI] [PubMed] [Google Scholar]
- 8.Lu S, Chang H, Sun X, et al. Long-term outcomes of nasopharyngeal carcinoma in 148 children and adolescents. Medicine (Baltimore) 2016;95:e3445. doi: 10.1097/MD.0000000000003445. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Mertens R, Granzen B, Lassay L, et al. Treatment of nasopharyngeal carcinoma in children and adolescents: Definitive results of a multicenter study (NPC-91-GPOH) Cancer. 2005;104:1083–1089. doi: 10.1002/cncr.21258. [DOI] [PubMed] [Google Scholar]
- 10.Blanchard P, Lee A, Marguet S, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: An update of the MAC-NPC meta-analysis. Lancet Oncol. 2015;16:645–655. doi: 10.1016/S1470-2045(15)70126-9. [DOI] [PubMed] [Google Scholar]
- 11.Ribassin-Majed L, Marguet S, Lee AWM, et al. What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol. 2017;35:498–505. doi: 10.1200/JCO.2016.67.4119. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Casanova M, Bisogno G, Gandola L, et al. A prospective protocol for nasopharyngeal carcinoma in children and adolescents: The Italian Rare Tumors in Pediatric Age (TREP) project. Cancer. 2012;118:2718–2725. doi: 10.1002/cncr.26528. [DOI] [PubMed] [Google Scholar]
- 13.Casanova M, Özyar E, Patte C, et al. International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents. Cancer Chemother Pharmacol. 2016;77:289–298. doi: 10.1007/s00280-015-2933-2. [DOI] [PubMed] [Google Scholar]
- 14.Buehrlen M, Zwaan CM, Granzen B, et al. Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: Preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG. Cancer. 2012;118:4892–4900. doi: 10.1002/cncr.27395. [DOI] [PubMed] [Google Scholar]
- 15. doi: 10.4143/crt.2017.463. Li Y, Tang LQ, Liu LT, et al: Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma in children and adolescents: A matched cohort analysis. Cancer Res Treat 50:1304-1315, 2018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Sahai P, Mohanti BK, Sharma A, et al. Clinical outcome and morbidity in pediatric patients with nasopharyngeal cancer treated with chemoradiotherapy. Pediatr Blood Cancer. 2017;64:259–266. doi: 10.1002/pbc.26240. [DOI] [PubMed] [Google Scholar]
- 17.Chen Y-P, Guo R, Liu N, et al. Efficacy of the additional neoadjuvant chemotherapy to concurrent chemoradiotherapy for patients with locoregionally advanced nasopharyngeal carcinoma: A Bayesian Network meta-analysis of randomized controlled trials. J Cancer. 2015;6:883–892. doi: 10.7150/jca.11814. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Wang M, Tian H, Li G, et al. Significant benefits of adding neoadjuvant chemotherapy before concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A meta-analysis of randomized controlled trials. Oncotarget. 2016;7:48375–48390. doi: 10.18632/oncotarget.10237. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. doi: 10.1016/j.ijrobp.2015.01.002. Tan T, Lim WT, Fong KW, et al: Concurrent chemo-radiation with or without induction gemcitabine, carboplatin, and paclitaxel: A randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 91:952-960, 2015. [DOI] [PubMed] [Google Scholar]
- 20.Frikha M, Auperin A, Tao Y, et al. A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02) Ann Oncol. 2018;29:731–736. doi: 10.1093/annonc/mdx770. [DOI] [PubMed] [Google Scholar]
- 21.Hong RL, Hsiao CF, Ting LL, et al. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study. Ann Oncol. 2018;29:1972–1979. doi: 10.1093/annonc/mdy249. [DOI] [PubMed] [Google Scholar]
- 22.Li WF, Chen NY, Zhang N, et al. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial. Int J Cancer. 2019;145:295–305. doi: 10.1002/ijc.32099. [DOI] [PubMed] [Google Scholar]
- 23.Fleming ID, Cooper JS, Henson DE, et al. AJCC Cancer Staging Manual. ed 5. Philadelphia, PA, : Lippincott-Raven; 1997. [Google Scholar]
- 24.Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18:3339–3345. doi: 10.1200/JCO.2000.18.19.3339. [DOI] [PubMed] [Google Scholar]
- 25.Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481. [Google Scholar]
- 26.Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343–346. doi: 10.1016/0197-2456(96)00075-x. [DOI] [PubMed] [Google Scholar]
- 27. Kalbfleisch J, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, John Wiley and Sons, 2002.
- 28.Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141–1154. [Google Scholar]
- 29. doi: 10.1016/j.ejca.2015.04.027. Yan M, Kumachev A, Siu LL, et al: Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis. Eur J Cancer 51:1570-1579, 2015. [DOI] [PubMed] [Google Scholar]
- 30.Liu M, You W, Song Y-B, et al. The changing role of chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A updated systemic review and network meta-analysis. Front Oncol. 2018;8:597. doi: 10.3389/fonc.2018.00597. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Yu H, Gu D, He X, et al. The role of induction and adjuvant chemotherapy in combination with concurrent chemoradiotherapy for nasopharyngeal cancer: A Bayesian network meta-analysis of published randomized controlled trials. OncoTargets Ther. 2016;9:159–170. doi: 10.2147/OTT.S96983. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Chen YP, Wang ZX, Chen L, et al. A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Ann Oncol. 2015;26:205–211. doi: 10.1093/annonc/mdu507. [DOI] [PubMed] [Google Scholar]
- 33.Carioli G, Negri E, Kawakita D, et al. Global trends in nasopharyngeal cancer mortality since 1970 and predictions for 2020: Focus on low-risk areas. Int J Cancer. 2017;140:2256–2264. doi: 10.1002/ijc.30660. [DOI] [PubMed] [Google Scholar]
- 34.Sun X, Tong LP, Wang YT, et al. Can global variation of nasopharynx cancer be retrieved from the combined analyses of IARC Cancer Information (CIN) databases? PLoS One. 2011;6:e22039. doi: 10.1371/journal.pone.0022039. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Makowska A, Wahab L, Braunschweig T, et al. Interferon beta induces apoptosis in nasopharyngeal carcinoma cells via the TRAIL-signaling pathway. Oncotarget. 2018;9:14228–14250. doi: 10.18632/oncotarget.24479. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Du CR, Ying HM, Kong FF, et al. Concurrent chemoradiotherapy was associated with a higher severe late toxicity rate in nasopharyngeal carcinoma patients compared with radiotherapy alone: A meta-analysis based on randomized controlled trials. Radiat Oncol. 2015;10:70. doi: 10.1186/s13014-015-0377-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. doi: 10.1016/j.ijrobp.2018.05.060. McDowell LJ, Rock K, Xu W, et al: Long-term late toxicity, quality of life, and emotional distress in patients with nasopharyngeal carcinoma treated with intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 102:340-352, 2018. [DOI] [PubMed] [Google Scholar]
- 38.Zhang B, Mo Z, Du W, et al. Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis. Oral Oncol. 2015;51:1041–1046. doi: 10.1016/j.oraloncology.2015.08.005. [DOI] [PubMed] [Google Scholar]
- 39.Fei Z, Chen C, Huang Y, et al. Metabolic tumor volume and conformal radiotherapy based on prognostic PET/CT for treatment of nasopharyngeal carcinoma. Medicine (Baltimore) 2019;98:e16327. doi: 10.1097/MD.0000000000016327. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Cheuk DK, Sabin ND, Hossain M, et al. PET/CT for staging and follow-up of pediatric nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2012;39:1097–1106. doi: 10.1007/s00259-012-2091-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Lee AW, Tung SY, Ngan RK, et al: Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials. Eur J Cancer 47:656-666, 2011. [DOI] [PubMed]
- 42.Peng L, Liu JQ, Xu C, et al. The prolonged interval between induction chemotherapy and radiotherapy is associated with poor prognosis in patients with nasopharyngeal carcinoma. Radiat Oncol. 2019;14:9. doi: 10.1186/s13014-019-1213-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. doi: 10.1016/j.ejca.2018.10.020. Li XY, Chen QY, Sun XS, et al: Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma. Eur J Cancer 110:24-31, 2019. [DOI] [PubMed] [Google Scholar]
- 44.Basso S, Zecca M, Merli P, et al. T cell therapy for nasopharyngeal carcinoma. J Cancer. 2011;2:341–346. doi: 10.7150/jca.2.341. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Louis CU, Straathof K, Bollard CM, et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010;33:983–990. doi: 10.1097/CJI.0b013e3181f3cbf4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. doi: 10.1038/mt.2013.242. Chia WK, Teo M, Wang WW, et al: Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol Ther 22:132-139, 2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Hsu C, Lee S-H, Ejadi S, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal Carcinoma: Results of the KEYNOTE-028 study. J Clin Oncol. 2017;35:4050–4056. doi: 10.1200/JCO.2017.73.3675. [DOI] [PubMed] [Google Scholar]
- 48.Ma BBY, Lim W-T, Goh B-C, et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: An international, multicenter study of the Mayo Clinic Phase 2 Consortium (NCI-9742) J Clin Oncol. 2018;36:1412–1418. doi: 10.1200/JCO.2017.77.0388. [DOI] [PMC free article] [PubMed] [Google Scholar]






